share_log

TG Therapeutics Presented Updated Data From The ENHANCE Phase 3b Trial Evaluating BRIUMVI (Ublituximab-xiiy) In Patients With Relapsing Forms Of Multiple Sclerosis (RMS)

Benzinga ·  Sep 18 19:21
TG Therapeutics Presented Updated Data From The ENHANCE Phase 3b Trial Evaluating BRIUMVI (Ublituximab-xiiy) In Patients With Relapsing Forms Of Multiple Sclerosis (RMS)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment